Skip to main content
SpringerLink
Log in

In the Heat of the Artery: Inflammation as Trigger and Target of Atherosclerosis

  • Chapter
  • First Online:
Platelets, Haemostasis and Inflammation

Part of the book series: Cardiac and Vascular Biology ((Abbreviated title: Card. vasc. biol.,volume 5))

  • 936 Accesses

Abstract

Abundant experimental and clinical work identifies inflammation of the vessel wall as a crucial factor in the development of atherosclerosis. Low-density lipoprotein (LDL) cholesterol initiates besides other factors endothelial activation. Monocytes and other immune cells invade the nascent lesion and create a pro-inflammatory milieu ultimately facilitating plaque rupture, the pathologic correlate of an acute coronary syndrome. We particularly shed light on the basic and clinical data implicating inflammation and immunity with this disease and its clinical sequelae. Furthermore, we comment on the large phase III CANTOS trial investigating the effect of an anti-inflammatory treatment with the IL-1b antibody canakinumab in over 10,000 patients with coronary heart disease and inflammatory status. This proof-of-concept trial showed for the first time that anti-inflammatory treatment may be a feasible and working option for patients with coronary heart disease. Finally, we end with an outlook on other promising targets for therapeutic intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA, World Heart Federation, The Preventive Cardiovascular Nurses Association. Aha/accf secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the american heart association and american college of cardiology foundation. Circulation. 2011;124:2458–73.

    Article  PubMed  Google Scholar 

  2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.

    Article  CAS  PubMed  Google Scholar 

  3. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest. 2013;123:27–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38:1092–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wolf D, Stachon P, Bode C, Zirlik A. Inflammatory mechanisms in atherosclerosis. Hamostaseologie. 2014;34:63–71.

    Article  CAS  PubMed  Google Scholar 

  6. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–12.

    Article  CAS  PubMed  Google Scholar 

  7. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–91.

    Article  CAS  PubMed  Google Scholar 

  8. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976;295:369–77.

    Article  CAS  PubMed  Google Scholar 

  9. Zirlik A, Lutgens E. An inflammatory link in atherosclerosis and obesity.Co-stimulatory molecules. Hamostaseologie. 2015;35:272–8.

    Article  CAS  PubMed  Google Scholar 

  10. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002;1:1.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hagiwara E, Takahashi KI, Okubo T, Ohno S, Ueda A, Aoki A, Odagiri S, Ishigatsubo Y. Cigarette smoking depletes cells spontaneously secreting th(1) cytokines in the human airway. Cytokine. 2001;14:121–6.

    Article  CAS  PubMed  Google Scholar 

  12. Marchini T, Wolf D, Michel NA, Mauler M, Dufner B, Hoppe N, Beckert J, Jackel M, Magnani N, Duerschmied D, Tasat D, Alvarez S, Reinohl J, von Zur MC, Idzko M, Bode C, Hilgendorf I, Evelson P, Zirlik A. Acute exposure to air pollution particulate matter aggravates experimental myocardial infarction in mice by potentiating cytokine secretion from lung macrophages. Basic Res Cardiol. 2016;111:44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–89.

    Article  CAS  PubMed  Google Scholar 

  14. McEver RP, Cummings RD. Role of psgl-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997;100:S97–103.

    Article  CAS  PubMed  Google Scholar 

  15. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Hackeng TM, Weber C. Heterophilic interactions of platelet factor 4 and rantes promote monocyte arrest on endothelium. Blood. 2005;105:924–30.

    Article  CAS  Google Scholar 

  16. Chan JR, Hyduk SJ, Cybulsky MI. Chemoattractants induce a rapid and transient upregulation of monocyte alpha4 integrin affinity for vascular cell adhesion molecule 1 which mediates arrest: an early step in the process of emigration. J Exp Med. 2001;193:1149–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sigal A, Bleijs DA, Grabovsky V, van Vliet SJ, Dwir O, Figdor CG, van Kooyk Y, Alon R. The lfa-1 integrin supports rolling adhesions on icam-1 under physiological shear flow in a permissive cellular environment. J Immunol. 2000;165:442–52.

    Article  CAS  PubMed  Google Scholar 

  18. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein e. Proc Natl Acad Sci USA. 1995;92:8264–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19.

    Article  CAS  PubMed  Google Scholar 

  20. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, Weissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA. 2006;103:10340–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195–205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Stoneman V, Braganza D, Figg N, Mercer J, Lang R, Goddard M, Bennett M. Monocyte/macrophage suppression in cd11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res. 2007;100:884–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lindau A, Hardtner C, Hergeth SP, Blanz KD, Dufner B, Hoppe N, Anto-Michel N, Kornemann J, Zou J, Gerhardt LM, Heidt T, Willecke F, Geis S, Stachon P, Wolf D, Libby P, Swirski FK, Robbins CS, McPheat W, Hawley S, Braddock M, Gilsbach R, Hein L, von zur Muhlen C, Bode C, Zirlik A. Hilgendorf I Atheroprotection through syk inhibition fails in established disease when local macrophage proliferation dominates lesion progression. Basic Res Cardiol. 2016;111:20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Stachon P, Ahrens I, Bode C, Zirlik A. Dual pathway therapy in acute coronary syndrome. J Thromb Thrombolysis. 2016;42:254–60.

    Article  CAS  PubMed  Google Scholar 

  27. Greaves DR, Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res. 2009;50(Suppl):S282–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. Nlrp3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wolf D, Zirlik A, Ley K. Beyond vascular inflammation—recent advances in understanding atherosclerosis. Cell Mol Life Sci. 2015;72:3853–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, Welch C, Tall AR. Combined deficiency of abca1 and abcg1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117:3900–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565–9.

    CAS  PubMed  Google Scholar 

  33. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol. 2006;26:2421–32.

    Article  CAS  PubMed  Google Scholar 

  34. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci USA. 2005;102:1596–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the ldlr-deficient mouse. Arterioscler Thromb Vasc Biol. 2003;23:454–60.

    Article  CAS  PubMed  Google Scholar 

  36. Hori S, Nomura T, Sakaguchi S. Control of regulatory t cell development by the transcription factor foxp3. Science. 2003;299:1057–61.

    Article  CAS  PubMed  Google Scholar 

  37. Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, Paulsson-Berne G, Hansson GK. Inhibition of t cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. 2010;207:1081–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost. 2011;106:779–86.

    Article  CAS  PubMed  Google Scholar 

  39. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein e-deficient mice. Circulation. 2007;115:2516–25.

    Article  CAS  PubMed  Google Scholar 

  40. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between streptococcus pneumoniae and oxidized ldl. Nat Med. 2003;9:736–43.

    Article  CAS  PubMed  Google Scholar 

  41. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, Tipping P, Bobik A, Toh BH. Depletion of b2 but not b1a b cells in baff receptor-deficient apoe mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS One. 2012;7:e29371.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Nilsson J, Hansson GK. The changing face of atherosclerotic plaque inflammation. J Intern Med. 2015;278:430–2.

    Article  CAS  PubMed  Google Scholar 

  43. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969–79.

    Article  CAS  PubMed  Google Scholar 

  44. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995;92:3893–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wolf D, Hohmann JD, Wiedemann A, Bledzka K, Blankenbach H, Marchini T, Gutte K, Zeschky K, Bassler N, Hoppe N, Rodriguez AO, Herr N, Hilgendorf I, Stachon P, Willecke F, Duerschmied D, von zur Muhlen C, Soloviev DA, Zhang L, Bode C, Plow EF, Libby P, Peter K, Zirlik A. Binding of cd40l to mac-1’s i-domain involves the eqlkksktl motif and mediates leukocyte recruitment and atherosclerosis—but does not affect immunity and thrombosis in mice. Circ Res. 2011;109:1269–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schonbeck U, Bode C, Libby P, Peter K. Cd40 ligand mediates inflammation independently of cd40 by interaction with mac-1. Circulation. 2007;115:1571–80.

    Article  CAS  PubMed  Google Scholar 

  47. Schonbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of cd40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA. 2000;97:7458–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Missiou A, Rudolf P, Stachon P, Wolf D, Varo N, Aichele P, Colberg C, Hoppe N, Ernst S, Munkel C, Walter C, Sommer B, Hilgendorf I, Nakano H, Bode C, Zirlik A. Traf5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res. 2010;107:757–66.

    Article  CAS  PubMed  Google Scholar 

  49. Stachon P, Missiou A, Walter C, Varo N, Colberg C, Wolf D, Buchner M, von Zur MC, Zirlik K, Bode C, Zirlik A. Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. PLoS One. 2010;5:e11589.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Missiou A, Kostlin N, Varo N, Rudolf P, Aichele P, Ernst S, Munkel C, Walter C, Stachon P, Sommer B, Pfeifer D, Zirlik K, MacFarlane L, Wolf D, Tsitsikov E, Bode C, Libby P, Zirlik A. Tumor necrosis factor receptor-associated factor 1 (traf1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation. 2010;121:2033–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, Ernst S, Aikawa M, Nakano H, Tsitsikov E, Schonbeck U. Traf-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of cd40l in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:1101–7.

    Article  CAS  PubMed  Google Scholar 

  52. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, Eklund KK. Cholesterol crystals activate the nlrp3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010;5:e11765.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Tschopp J, Schroder K. Nlrp3 inflammasome activation: the convergence of multiple signalling pathways on ros production? Nat Rev Immunol. 2010;10:210–5.

    Article  CAS  PubMed  Google Scholar 

  54. Stachon P, et al. P2X7 deficiency blocks lesional inflammasome activity and ameliorates atherosclerosis in mice. Circulation. 2017;135(25):2524–33. https://doi.org/10.1161/CIRCULATIONAHA.117.027400.

    Article  CAS  PubMed  Google Scholar 

  55. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986;78:1432–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Stachon P, Geis S, Peikert A, Heidenreich A, Michel NA, Unal F, Hoppe N, Dufner B, Schulte L, Marchini T, Cicko S, Ayata K, Zech A, Wolf D, Hilgendorf I, Willecke F, Reinohl J, von Zur MC, Bode C, Idzko M, Zirlik A. Extracellular atp induces vascular inflammation and atherosclerosis via purinergic receptor y2 in mice. Arterioscler Thromb Vasc Biol. 2016;36:1577–86.

    Article  CAS  PubMed  Google Scholar 

  57. Stachon P, Peikert A, Michel NA, Hergeth S, Marchini T, Wolf D, Dufner B, Hoppe N, Ayata CK, Grimm M, Cicko S, Schulte L, Reinohl J, von zur Muhlen C, Bode C, Idzko M, Zirlik A. P2y6 deficiency limits vascular inflammation and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014;34:2237–45.

    Article  CAS  PubMed  Google Scholar 

  58. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–71.

    Article  CAS  PubMed  Google Scholar 

  59. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278:483–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33–43.

    Article  CAS  PubMed  Google Scholar 

  61. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriosclerosis Thromb. 1991;11:1223–30.

    Article  CAS  Google Scholar 

  62. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.

    Article  CAS  PubMed  Google Scholar 

  64. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354–63.

    Article  CAS  PubMed  Google Scholar 

  65. Quillard T, Araujo HA, Franck G, Shvartz E, Sukhova G, Libby P. Tlr2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J. 2015;36:1394–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol. 2002;22:788–92.

    Article  CAS  PubMed  Google Scholar 

  67. Ridker PM. Establishing a clinical basis for hscrp in the prevention and treatment of cardiovascular disease. Clin Chem. 2010;56:1186–7.

    Article  CAS  PubMed  Google Scholar 

  68. Libby P. Murine “model” monotheism: an iconoclast at the altar of mouse. Circ Res. 2015;117:921–5.

    Article  CAS  PubMed  Google Scholar 

  69. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JTS. Reduction in c-reactive protein and ldl cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the jupiter trial. Lancet. 2009;373:1175–82.

    Article  CAS  PubMed  Google Scholar 

  70. Stability Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, Lopez-Sendon J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702–11.

    Article  CAS  Google Scholar 

  71. O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Investigators S-T, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the solid-timi 52 randomized clinical trial. JAMA. 2014;312:1006–15.

    Article  PubMed  CAS  Google Scholar 

  72. Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. Cetp inhibition: past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Howes LG. Selective cox-2 inhibitors, nsaids and cardiovascular events – is celecoxib the safest choice? Ther Clin Risk Manag. 2007;3:831–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, Lansky AJ, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: the biorest liposomal alendronate with stenting study (blast)-a double blind, randomized clinical trial. Am Heart J. 2013;165:234–40. e231

    Article  CAS  PubMed  Google Scholar 

  75. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity c-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99:805–7.

    Article  CAS  PubMed  Google Scholar 

  76. Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, Cronstein BN, Sedlis SP, Pillinger MH. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Sari I, Yuksel A, Kozaci D, Selcuk S, Gokce G, Yildiz Y, Demirel H, Sop G, Alacacioglu A, Gunay N, Akkoc N. The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial mediterranean fever. Inflammation. 2012;35:1191–7.

    Article  CAS  PubMed  Google Scholar 

  78. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–10.

    Article  CAS  PubMed  Google Scholar 

  79. Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015;132:1395–403.

    Article  CAS  PubMed  Google Scholar 

  80. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, Group CPI. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin a1c, lipids, c-reactive protein, interleukin-6, and fibrinogen: a phase iib randomized, placebo-controlled trial. Circulation. 2012;126:2739–48.

    Article  CAS  PubMed  Google Scholar 

  81. Kisiel B, Kruszewski R, Juszkiewicz A, Raczkiewicz A, Bachta A, Tlustochowicz M, Staniszewska-Varga J, Klos K, Duda K, Boguslawska-Walecka R, Ploski R, Tlustochowicz W. Methotrexate, cyclosporine a, and biologics protect against atherosclerosis in rheumatoid arthritis. J Immunol Res. 2015;2015:759610.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (cirt). J Thromb Haemost. 2009;7(Suppl 1):332–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Faculty, Department of Cardiology and Angiology I, University Heart Center Freiburg, University of Freiburg, Hugstetter Street 55, 79106, Freiburg, Germany

    Peter Stachon & Andreas Zirlik

Authors
  1. Peter Stachon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Zirlik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Zirlik .

Editor information

Editors and Affiliations

  1. Cardiology and Angiology I, University-Heart Center Freiburg, Freiburg, Germany

    Andreas Zirlik

  2. Cardiology and Angiology I, University-Heart Center Freiburg, Freiburg, Germany

    Christoph Bode

  3. Department of Cardiology, University Hospital Tübingen, Tübingen, Germany

    Meinrad Gawaz

Compliance with Ethical Standards

Compliance with Ethical Standards

  • Conflict of Interest: Peter Stachon and Andreas Zirlik declares that they have no conflict of interest.

  • Ethical Approval: This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Stachon, P., Zirlik, A. (2017). In the Heat of the Artery: Inflammation as Trigger and Target of Atherosclerosis. In: Zirlik, A., Bode, C., Gawaz, M. (eds) Platelets, Haemostasis and Inflammation. Cardiac and Vascular Biology, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-319-66224-4_2

Download citation

Publish with us

Policies and ethics

Search

Navigation